Photo: Fotolia

MyoKardia Inc. has hired Cynthia Ladd as general counsel, the company has announced. Ladd, a biopharmaceutical in-house veteran, comes to the company from CytomX Therapeutics Inc., where she was senior vice president and GC.

Based in South San Francisco and founded in 2012, MyoKardia is a clinical-stage biotech that focuses on heart disease. Last August, shares of its stock soared after a midstage study of one of its experimental drugs, mavacamten, showed strong results in a small trial involving patients with a genetic heart condition, according to a San Francisco Business Times report.

“As MyoKardia continues to grow as a company with mavacamten entering late-stage clinical development and our portfolio of targeted cardiovascular therapeutics advancing, Cynthia's extensive experience and leadership will be highly valued,” MyoKardia CEO Tassos Gianakakos said in a statement.

Before joining CytomX in 2015, Ladd held several high-ranking in-house positions at various biopharma companies, including AGY Therapeutics Inc., Pharmacyclics and Genentech Inc. She began her legal career at Wilson Sonsini Goodrich & Rosati and later Ware & Freidenrich (now DLA Piper.)

She holds degrees from Pennsylvania State University and Stanford Law School, as well as Cornell University, where she earned a master's in animal nutrition and biochemistry.

A MyoKardia spokesperson did not immediately respond to an emailed request for comment Monday morning about Ladd's hire, including whether she is the first person to hold the top lawyer position at the company.